Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Official title

A Single Arm, Open Label, Single-center Dose-exploratory Clinical Study of Linperlisib in Combination With EZH2 Inhibitor SHR2554 in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Overview

This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.

Detailed description

Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total. The BOIN Waterfall design was employed to divide these six groups into two sub-trials.

Initially, three participants will be recruited into the lowest dose group of the first sub-trial: Linperlisib (40mg QD) and SHR2554 (150mg BID). After completing the dose-limiting toxicity (DLT) observation period, the next dose group will begin. Once DLT evaluations for the three participants are completed, the statistician will review the safety data and, following the decision-making flowchart of the BOIN design, determine whether to escalate to the next dose level. Another three participants will be enrolled and evaluated, continuing this process until all dose combinations in the first sub-trial have been tested, the sample size is depleted, or a stopping rule is triggered. Based on the results of the first sub-trial, the statistician will assess and select the starting dose for the second sub-trial, repeating the process until the trial is complete.

Interventions

• Drug linperlisib and SHR2554
  Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.

Primary outcome measures

• Maximum Tolerated Dose (MTD) of linperlisib in combination with SHR2554 [Time frame: 28 days since the date of first dose]

Secondary outcome measures (5)

• Safety of linperlisib in combination with SHR2554 [Time frame: From the start of treatment until 30 days after the last treatment]
• Overall response rate (ORR) [Time frame: 2 years]
• Complete response (CR) rate [Time frame: 2 years]
• Progression-free survival (PFS) [Time frame: 2 years]
• Overall survival (OS) [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

• Age ≥18 years old, male or female;
• Pathologically confirmed PTCL, including systemic anaplastic large cell lymphoma (ALCL), peripheral T cell lymphoma non-specific type (PTCL NOS), lymph node T-follicular helper cell lymphoma (nTFHL) \[including nTFHL angioimmunoblastic type (NTFHL-AI), nTFHL follicular type (NTFHL-F) and nTFHL non-specific name (NTFHL-NOS)\], enteropathy-associated T-cell lymphoma and hepato-splenic T-cell lymphoma;
• Have received at least one previous systemic therapy, ALCL patients must have received CD30-targeted therapy; Patients were allowed to have received hematopoietic stem cell transplantation;
• There must be at least one evaluable lesion/measurable lesion that meets the 2014 version of Lugano lymphoma evaluation criteria \[Evaluable lesion
• ECOG PS 0-2;
• Adequate organ function:
• Expected survival of at least 3 months;
• Fertile male and female subjects are willing to use effective contraceptive measures throughout the study period and for six months after the last dose.
• Volunteer to participate in clinical studies and sign informed consent, willing to follow and able to complete all trial procedures.

Exclusion criteria

If a patient has any of the following conditions should not be included in this study:

• Had been treated with PI3K inhibitor or EZH2 inhibitor or EZH1/2 inhibitor before enrollment;
• Primary cutaneous T-cell lymphoma;
• History of other primary aggressive malignancies that are not in remission or in remission for no more than 3 years;
• Involvement of the central nervous system (meninges or brain parenchyma);
• People with a known allergy to any of the drugs in the study
• Participated in other drug clinical trials within 4 weeks before the study began;
• Pregnant or lactating women;
• Active infected persons, except tumor-related B symptom fever;
• Diseases and medical history:

• have multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
• have a history of psychotropic substance abuse and can not quit or have mental disorders;
• Subjects with any severe and/or uncontrolled medical condition;
• A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• Other situations deemed unsuitable for inclusion in the study by the researcher.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06712173 · IIT2024029

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗